To assess the effect of ablative therapy (Photodynamic Therapy or Radiofrequency ablation )
on Barrett's Esophagus
To assess the effect of ablation therapy on Barrett's esophagus. Proposal Ablation therapy
is an FDA approved treatment to decrease cancer risk in Barrett's esophagus mucosa. This is
being performed in our Barrett's Esophagus Unit on a regular basis. However, the longterm
outcomes of this therapy is not established and there are patients who have been treated who
later re-develop Barrett's mucosa. This study will allow us store tissue samples that can
later be used to assess the effect of ablative therapy on Barrett's esophagus.
- Patients who have had or qualify for ablation therapy for treatment of their
barrett's esophagus with high grade dysplasia or early esophageal adenocarcinoma
- Ability to provide informed consent
- Eastern Cooperative Oncology Group performance status 3 or 4
- Inability to tolerate endoscopic procedures
- Pregnancy: Females of child-bearing age will be screened with pregnancy test.